Abstract
Constitutive activation of G protein-coupled receptors (GPCRs) is now well recognized and many classical GPCR antagonists have been found to be inverse agonists. For the α2A-adrenergic receptor (AR) we determine the relative inverse efficacies of a series of antagonists and utilize the extended ternary complex model to estimate the fraction of constitutively active mutant (CAM) receptors in the active state. Stable Chinese hamster ovary cell lines expressing the porcine α2A-AR in its wild-type (WT) and constitutively activated (CAM-T373K) form were isolated. Activation of both Gi and Gs was enhanced for CAM receptors. cAMP production was suppressed in cells with the CAM α2A-AR and this suppression was reversed by α2-adrenergic antagonists with an order of inverse efficacy of rauwolscine > yohimbine > RX821002 > MK912, whereas phentolamine and idazoxan were essentially neutral antagonists. This striking difference in inverse efficacy between idazoxan and RX821002 may account for in vivo pharmacological differences between these two α2-adrenergic antagonists. Agonist binding affinity to the non-G protein-coupled CAM receptor was 3- to 9-fold higher than to WT, whereas binding of the most efficacious inverse agonists, yohimbine and rauwolscine, was 1.7- and 2.1-fold weaker. Analysis of this difference by the extended ternary complex model indicates that approximately 50% of the CAM α2A-AR is in the active (R*) state although there is no detectable constitutive activity of the WT receptor in the absence of agonist.
Footnotes
- Received June 12, 2000.
- Accepted November 17, 2000.
-
Send reprint requests to: Dr. Richard R. Neubig, Department of Pharmacology, 1301 MSRB III, 1150 W. Medical Center Dr., Ann Arbor, MI 48109-0632. E-mail: RNeubig{at}umich.edu
-
Supported by National Institutes of Health HL46417. Production and flow cytometry screening of the mutant receptors received assistance from UM-MAC, National Institutes of Health P60-AR20557.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|